View ValuationAdia Nutrition 将来の成長Future 基準チェック /06現在、 Adia Nutritionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長33.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.お知らせ • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.お知らせ • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.お知らせ • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.お知らせ • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Adia Nutrition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ADIA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261000N/A12/31/20251000N/A12/31/20240000N/Aアナリストによる今後の成長予測収入対貯蓄率: ADIAの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ADIAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ADIAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ADIAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ADIAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ADIAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 01:48終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Adia Nutrition, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.
お知らせ • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.
お知らせ • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.
お知らせ • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
お知らせ • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0